Would you ever pay \$20 for a Starbucks Coffee?

Troy Trygstad, PharmD MBA PhD

Disclaimer(s)

- I practice community pharmacy on nights and weekends
 - I'm pro pharmacist and primary care
- I lead a nationwide clinically integrated network of 3,300 pharmacies
 - 4th largest "chain" by single signature in the United States
- I'm also a pharmaceutical health policy/health services researcher by training
 - View the world through the lens of economics

Agenda


- Where does the money go?
- Drugs are expensive (sometimes).
- Pharmacy is not expensive.
- The disconnect.
- The \$20 Starbucks Coffee
- "Rents".
- Benchmark pricing.
- Value Based Contracting.
- Pharmacy Quality Networks.
- Results.

US health spending is much greater for all categories of care, particularly for ambulatory care and administration cost

2010 (or latest year available)

Where does the money go?

(Hint: it's worse with non-Rx categories)




Note: Health spending excludes investments. The percentages in the US bar indicate how much more the US spends per category compared with the average of the five other OECD countries. Source: OECD Health Data 2012.

Where does the money go?

(Hint: Pareto would blush)

• Source: Express Scripts, "2018 Drug Trend Report," February 2019




https://www.managedcaremag.com/archives/2019/9/specialty-drug-spend-soars-can-formulary-management-bring-it-down-earth

Express Scripts, Components of Change in Net Drug Spending, Traditional vs. Specialty, 2019

Drugs are expensive.


(Some of them, but not many)



Source: Drug Channels Institute analysis of Express Scripts drug trend report. Figures are for Express Scripts' commercial clients and include the effect of rebates.

Published on Drug Channels (www.DrugChannels.net) on February 25, 2020.





IQVIA Institute. Medicine use and spending in the US: a review of 2017 and outlook to 2022. https://www.iqvia.com/Institute/Reports/Medicine-Use-And-Spending-In-The-Us-Review-Of-2017-Outlook-To-2022. Published April 19, 2018. Assumes 3.5% inflation for 2 years after 2017.

The disconnect(s).


(Small number of fills, big % of cost)

Spend

"Specialty Medications"

"Regular Medications"

Rx Fills



"Regular Medications"

PBM Business Models

(business model migration over time)

Administration Phase (70s, early 80s)

profits by administrative efficiencies

Generic Conversion Phase (late 80s, 90s)

profits by brand to generic conversions

Rebates Phase (early, 00s, 10s)

profits by drug rebates, some b2g

Spread Phase (late 00s, 10s)

- profits by drug rebates, spread pricing

Vertical Integration Phase (late 00s, 20s)

profits by channeling, profit-shifting

Ever pay \$20 for a Starbucks Coffee?

(If you bought it from a PBM you might)





Ever pay \$20 for a Starbucks Coffee?

(Coffee is very cheap to procure and produce)

	Dr. Penny Pincher	
Cost for 16 oz:	\$	0.11
Coffee maker	\$	0.01
Water	\$	0.00
Electricity	\$	0.01
Filter	\$	0.01
Coffee grounds	\$	0.08
Cheap 16 oz Coffee	Cost	

Ever pay \$20 for a Starbucks Coffee?

(If you bought it from a PBM you might)


Latte price breakdown


Matt Milletto of the American Barista & Coffee School breaks down the \$3 cost of a




+ \$2-\$17+

To Administer







Drawn to Scale for 2021

From Transparency to Opacity

("Rents" require market confuscation)


PBM Admin Fee

Administration Phase (70s, early 80s)

Generic Conversion Phase (late 80s, 90s)



Rebates Phase (early, 00s, 10s)




Sponsor Paid Pharmacy For Drug

Rebate + Admin Fee + "Spread"

PBM Rebate +Admin Fee

Spread Phase (late 00s, 10s)

Vertical Integration Phase (late 00s, 20s)



Sponsor Paid Pharmacy For Drug PBM Rebate + Admin Fee + "Spread"

The rise of discount cards.

(How is it that insured individuals elect NOT to use their insurance?)

Pharmacy Paid
For Drug

Pharmacy Reimbursed For Drug

Pharmacy "Cash" Price

Sponsor Paid Pharmacy For Drug

Forced Patient
Out of Pocket

GoodR



...and many others...
including now *In-House*PBM/Insurer Cards!



MILLIMAN WHITE PAPER

NADAC-plus: An emerging paradigm in pharmacy pricing?

Kevin Pierce, ASA, MAAA Andrea Sheldon, FSA, MAAA



Due to drug price transparency concerns, cost-plus contracting is receiving greater attention. This paper discusses national average drug acquisition costs (NADAC) as a basis for cost-plus pricing.

With increased consumer and regulatory scrutiny on drug prices, stakeholders in the pharmacy supply chain are exploring drug pricing alternatives. The *cost-plus* pricing method establishes drug prices based on acquisition costs plus an explicit spread or fee. *NADAC-plus* pricing is a form of *cost-plus* pricing that relies on NADAC as a reference. This paper introduces NADAC and describes the opportunities and limitations of using NADAC as a basis for pharmacy pricing.

What is NADAC?

NADAC estimates the national average drug invoice price paid by independent and retail chain pharmacies. NADAC excludes specialty and mail order pharmacies, and does not reflect How does NADAC compare to AWP?



Recommended Read

Benchmark pricing.

Average Wholesale Price ("Aint' What's Paid")

(NADAC)

QUESTIONS & ANSWERS
ANSWER
National average drug acquisition cost for retail pharmacies.
Independent and retail chain pharmacies voluntarily contribute.
Drug invoice prices are included. Rebates, price concessions, and off- invoice discounts are excluded. Specialty and mail order pharmacies are excluded.
Random surveys are conducted monthly. NADAC datasets are updated weekly.
Average of voluntarily reported data by pharmacies. 450–600 pharmacies typically contribute per month.


utilization by drug type and business line. Please refer to the Methodology section for more information on our approach for developing the values in Figure 2.


FIGURE 2: NADAC EQUIVALENT DISCOUNTS OFF AWP USING OCTOBER 2018 NADAC AND OCTOBER 2018 AWP)

DRUG TYPE	MEDICARE	COMMERCIAL	MEDICAID
Generic	92.6%	90.3%	90.2%
Brand	20.1%	20.0%	20.0%
Specialty	24.8%	24.2%	21.8%

¹ "CMS Retail Price Survey, NADAC Overview and Help Desk Operations." Centers for Medicaid and Medicare Services. August 2017. Retrieved on October 30, 2018, from https://www.medicaid.gov/medicaid/prescription-drugs/downloads/retail-price-survey/nadac-overview-operations.pdf.

^{2 &}quot;National Average Drug Acquisition Cost (NADAC) Questions and Responses." Centers for Medicare and Medicaid Services. Retrieved on October 30, 2018, from https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/ful-nadac-downloads/nadacga.pdf.






Typical Pharmacy PBM Contract: "AWP – 82% + \$1.00 Dispensing Fee"


NADAC PBM Contract: "NADAC + \$8.50 Dispensing Fee"

The Difference?: A better benchmark of what the pharmacy paid for the drug and nearly all of payment is for the service.

Otherwise – you have no idea whatsoever what you are actually paying for the Coffee!

Imagine if Visa or Mastercard charged you a \$17 transaction fee on a cup of coffee






https://healthdata.gov/harvest_source/datamedicaidgov

Good Haircut

Bad Haircut



(Why did this trend miss Pharmacy Sector?)





....Same Reimbursement

(not related at all to medical outcomes...)

From a Retail Spread Business to...

...A Services-Based Business

Spend

"Specialty Medications"

"Regular Medications"

Rx Fills



"Regular Medications"

Touches

"Regular Medications" – Mail Order


"Regular Medications" - Community Based

More than 1 Billion Face-to-Face Opportunities Wasted Annually


Misalignment

How did pharmacy get here?

(Lack of Alignment...)



"I get paid to build tunnels!"



(Left out of Outcomes-based VBP conversation...)

Pharmacy Benefit Medical Benefit (Plan)

Medications

+

Services

Lower BP Lower A1c Lower Hosp. Lower Total \$\$

Supply of Services Demand for Outcomes

What does a Services-Based VBP program targeting clinical outcomes look like for pharmacies?

- Example Diabetes Program (Targeted Pts.)
 - Intervention
 - Patient goals
 - Medication Reconciliation
 - Problems medical problems, drug therapy problems, and health concerns
 - Plan of Care
 - Report Lab results: A1c, fasting blood glucose, and blood pressure
 - Data/Reporting
 - Electronic Care Plan

- Payment
 - \$60 & 80 PMPM
 - 25% Withheld
 - 80% Threshold
 - Engaged (Care Plan)
 - A1c Reported
 - 25% Threshold
 - A1c < 9.0
 - 50% Threshold
 - *A1c*<*9.0*

What does a Services-Based VBP program targeting clinical outcomes look like for pharmacies?


- Example Asthma Program
 - Intervention
 - Whatever works
 - Data/Reporting
 - None from Pharmacy
 - Claims analysis of ED visits

- Payment
 - \$10 PMPM
 - Shared Savings Upside
 - 65% of Savings to Pharmacy Network



PPCN Quality Data: HEDIS Performance


January 1- July 31, 2019



• **HEDIS**: <u>H</u>ealthcare <u>E</u>ffectiveness <u>D</u>ata and <u>I</u>nformation <u>S</u>et

Results.

Accountable Pharmacy Networks are not a Unicorn and Many Plans are Moving Toward Value-Based Pharmacy Contracting




• Sinclair J, Bentley OS, Abubakar A, Rhodes LA, Marciniak MW, Impact of Pharmacists in Improving Quality Measures that Affect Physician Payment, Journal of the American Pharmacists Association (2019), doi: https://doi.org/10.1016/j.japh.2019.03.013.

The Future.

Accountable Pharmacy Networks are not a Unicorn and Many Plans are Moving Toward Value-Based Pharmacy Contracting

INDUSTRY
TREND REPORT

https://www.pharmacyquality.c om/wpcontent/uploads/2020/11/PQSt rendreportinPharmacyQuality2 020.pdf EVIDENCE OF BIOMETRIC TEST RESULTS OR PHYSICAL ASSESSMENT FINDINGS FOR A QUALITY MEASURE IN ACCORDANCE WITH DATA SOURCE MANDATES (E.G., POINT OF CARE TESTING FOR HEMOGLOBIN A1C AND SUBMIT TESTING RESULTS; BLOOD PRESSURE MEASUREMENT FOR BLOOD PRESSURE CONTROL), HOW LIKELY ARE YOU TO CONTRACT WITH COMMUNITY PHARMACIES TO PERFORM THE SERVICE?



NOTE: 2019 N = 12; 2020 N = 13

Questions?